Neurocritical Care Society Issues New Ethical Roadmap for Organ Donation at the End of Life

When a devastating brain injury leaves a patient with no chance of meaningful recovery, the intensive care team faces one of medicine’s most delicate transitions: shifting from preserving life to honoring death, while a parallel possibility—that of organ donation—comes into focus. A new ethical guidance statement from the Neurocritical Care Society, published in the journal Neurocritical Care, now aims to give clinicians a clearer moral and practical compass for that journey. Led by Alexandra Reynolds of Hackensack University Medical Center and Matthew Jaffa of Hartford Hospital, with senior author Ariane Lewis of NYU Langone Medical Center, the statement responds directly to concerns raised by the society’s own members about how donation conversations, palliative care, and the boundaries between patient care and organ procurement are managed at the bedside.

The impetus for the statement was a 2025 survey of Neurocritical Care Society members that examined their experiences and attitudes surrounding organ donation. The survey revealed significant gaps in education among treatment teams about the donation process, along with opportunities to improve palliative interventions after withdrawal of life-sustaining therapies in patients who might become donation after cardiac death donors—cases where death is determined by the irreversible cessation of circulatory and respiratory function rather than by neurologic criteria. Respondents also flagged a cluster of ethical sore points: blurred boundaries between caring for the patient and caring for the organs, worries about transparency, empathy, and cultural sensitivity in how organ procurement organizations communicate with surrogate decision-makers, and unresolved questions about the ethics of first-person authorization, in which a donor’s prior registered consent supersedes family objections.

In response, the society’s Ethics Committee constructed a document that is part education, part ethical framework. Members were given the chance to comment on a draft between April 6 and 19, 2026, before the final statement was published on September 3, 2026. The statement takes the form of an informal narrative review of the literature pertinent to end-of-life care of potential donors, paired with practical guidance on three thorny areas: the legal definitions of death, first-person authorization, and collaborative communication, along with the management of potential conflicts of interest that inevitably arise when transplantation goals intersect with terminal care.

At the heart of the document lies a technical distinction that is easy to state but hard to operationalize: death determined by neurologic criteria, commonly called brain death, versus death determined by circulatory-respiratory criteria. Donation after brain death, in which organs are recovered after the donor has been declared dead by neurologic standards while the heart still beats, is well established. Donation after circulatory death is more ethically fraught, because it follows the withdrawal of life-sustaining therapy and the cessation of circulation. Timing is everything—organs deteriorate rapidly without blood flow, yet death must be declared before any procurement begins, in keeping with the dead donor rule, the foundational ethical principle that vital organs may only be removed from patients who are already dead. The statement situates donation after circulatory death within this legal and moral architecture, drawing on the Uniform Determination of Death Act, the 1981 President’s Commission report that established the dual standard for determining death in the United States, and the World Brain Death Project’s international consensus framework.

First-person authorization receives particularly close scrutiny. Under the Uniform Anatomical Gift Act, an individual’s documented decision to donate—registered through a department of motor vehicles or a donor registry—is legally binding, much like a will. Yet surveys show that families sometimes override a loved one’s registered consent, and clinicians report discomfort when a surrogate’s objections clash with the deceased’s explicit wishes. UK research has identified factors that triple the likelihood of families overriding first-person consent, and litigation in several American states has tested where legal authority truly rests. The statement’s guidance navigates this tension between legal gift law and the human reality of grieving families, acknowledging the ethical literature that questions whether registration practices fully honor autonomy while also recognizing that honoring a donor’s prior choice respects the person the patient once was.

Communication emerges as another central pillar. Studies cited in the statement show that the way death is communicated, the setting in which donation is discussed, and whether families feel supported rather than pressured all shape both consent outcomes and bereavement. Research on grief symptoms in relatives who experienced donation requests in the ICU, on the impact of in-person versus telephone approaches by procurement coordinators, and on family experiences after withdrawal of life-sustaining measures in Canada all point in the same direction: trust is built through early, empathetic, decoupled conversations in which the treatment team discusses prognosis and goals of care separately from any donation discussion, with organ procurement organizations engaged only after the decision to withdraw therapy has been made. Simulation-based communication training for clinicians and structured collaborative models between ICUs and donation agencies are highlighted as proven ways to raise the quality of these conversations.

The statement also addresses palliative care within the donation pathway, an area the 2025 survey identified as ripe for improvement. When life-sustaining therapy is withdrawn in anticipation of circulatory death, the patient must receive optimal symptom management—analgesia and sedation guided by the principle of double effect—while the donation team watches the clock. Predictive tools, from the University of Wisconsin evaluation tool to modern machine-learning models that estimate time to asystole, now allow clinicians to counsel families realistically about whether donation is likely to be feasible, reducing the harm of futile procurements in which death does not come quickly enough for organs to remain viable. The growing use of donor care units, dedicated facilities where potential donors are managed after authorization, represents a structural innovation aimed at improving organ quality, though it raises fresh questions about geographic access and the optics of moving a dying patient.

Conflicts of interest receive candid treatment. The document acknowledges the moral distress reported by anesthesiologists, nurses, and intensivists who participate in donation processes, and the professional tensions documented in a 2025 systematic review of ethical attitudes toward circulatory death donation in ICUs. It points to mechanisms such as the Organ Procurement and Transplantation Network’s misconduct reporting system and the decoupling of donation advocacy from bedside care as safeguards. The legacy of this concern stretches back decades—ethicists were debating the problems of procurement as early as 1964—but the current statement treats these tensions as manageable through clear role separation, transparency, and institutional ethics support rather than as reasons to abandon donation altogether.

The timing of the statement is notable. Demand for transplanted organs continues to outstrip supply worldwide, with chronic kidney disease alone imposing an enormous global burden, while xenotransplantation of genetically engineered pig organs, organ bioprinting, and regenerative medicine hover on the clinical horizon. Against that backdrop, the integrity of the deceased donation pathway—its legal definitions, its consent practices, its communication standards—matters more than ever. Recent congressional scrutiny of the organ procurement system, racial and ethnic disparities in donor referral, and contested cases involving unrepresented patients all underscore that public trust in donation is conditional. By codifying ethical guidance grounded in the lived experience of neurointensivists, the Neurocritical Care Society has produced a document intended not merely to increase the supply of organs, but to ensure that every step toward procurement is taken only after the patient has been fully cared for, fully honored, and fully dead according to law.

Subject of Research: Ethical guidance and education for organ donation at the end-of-life in neurocritical care

Article Title: Education and Ethical Guidance for Organ Donation at the End-of-Life: An Ethical Guidance Statement from the Neurocritical Care Society

Article References: Reynolds, A. S., Jaffa, M. N., McHugh, D., Babi, M. A., Cappucci, S., Condie, C., Durrant, J., Gandee, R., Lim-Hing, K., Runco, A., & Lewis, A. (2026). Education and Ethical Guidance for Organ Donation at the End-of-Life: An Ethical Guidance Statement from the Neurocritical Care Society. Neurocritical Care. https://doi.org/10.1007/s12028-026-02619-8

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02619-8

Keywords: organ donation, neurocritical care, brain death, donation after circulatory death, medical ethics, end-of-life care, first-person authorization, organ procurement organizations, dead donor rule, palliative care, withdrawal of life-sustaining therapy, surrogate decision-making